Denali Therapeutics Inc.
DNLI
$14.19
-$0.135-0.94%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -132.97M | -114.75M | -107.19M | -99.03M | -101.80M |
| Total Depreciation and Amortization | 3.21M | -5.28M | 2.27M | 1.94M | 2.16M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 20.22M | 25.76M | 15.43M | 14.02M | 1.83M |
| Change in Net Operating Assets | -21.93M | 10.56M | 30.35M | -8.16M | -15.81M |
| Cash from Operations | -131.47M | -83.72M | -59.14M | -91.22M | -113.62M |
| Capital Expenditure | -5.08M | -5.09M | -3.88M | -4.79M | -2.15M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 23.83M | 177.30M | 97.54M | 103.36M | -451.04M |
| Cash from Investing | 18.75M | 172.21M | 93.66M | 98.57M | -453.19M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -4.36M | -8.32M | -24.02M | -- | -- |
| Issuance of Common Stock | 595.00K | 4.16M | 5.94M | 6.76M | 500.76M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 0.00 | -480.00K | -- | -480.00K |
| Cash from Financing | -3.76M | -4.17M | -18.56M | 6.76M | 500.28M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -116.48M | 84.32M | 15.96M | 14.11M | -66.53M |